First Trust Advisors
TRDA icon

First Trust Advisors’s Entrada Therapeutics TRDA Stock Holding History

First Trust Advisors’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-75,120
Closed -$505K – 2734
2025
Q2 		$505K Buy
75,120
+2,631
+4% +$21.2K ﹤0.01% 2264
2025
Q1 		$655K Sell
72,489
-1,260
-2% -$15.7K ﹤0.01% 2166
2024
Q4 		$1.28M Sell
73,749
-7,800
-10% -$141K ﹤0.01% 1981
2024
Q3 		$1.3M Buy
+81,549
New +$1.28M ﹤0.01% 1933

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
Cantor Fitzgerald
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

First Trust Advisors's TRDA Position: Q3 2025 in Review

First Trust Advisors sold out of Entrada Therapeutics (TRDA) in Q3 2025, closing a stake of 75,120 shares — an estimated $505K sold.

First Trust Advisors first reported a position in TRDA in Q3 2024 and held it in 4 quarters. The position peaked at $1.3M in Q3 2024. 117 funds tracked by Wall St. Rank hold TRDA as of Q3 2025.

  • First Trust Advisors reported no remaining Entrada Therapeutics position as of Q3 2025 after selling out during the quarter.
  • First Trust Advisors sold 75,120 Entrada Therapeutics shares in Q3 2025, an estimated $505K.
  • First Trust Advisors first reported a position in Entrada Therapeutics in Q3 2024 and held it in 4 quarters.
  • First Trust Advisors's Entrada Therapeutics position peaked at $1.3M in Q3 2024.
  • 117 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2025.

Based on First Trust Advisors's 13F filing for Q3 2025, filed 12 Nov 2025.